Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Madrigal Pharmaceuticals Inc (MDGL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,503,718
  • Shares Outstanding, K 15,418
  • Annual Sales, $ 0 K
  • Annual Income, $ -32,810 K
  • 60-Month Beta 1.18
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.41

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -1.05
  • Number of Estimates 6
  • High Estimate -1.00
  • Low Estimate -1.09
  • Prior Year -0.45
  • Growth Rate Est. (year over year) -133.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
89.83 +12.20%
on 06/06/19
103.84 -2.94%
on 06/13/19
-2.32 (-2.25%)
since 05/17/19
3-Month
89.83 +12.20%
on 06/06/19
145.32 -30.64%
on 03/19/19
-37.62 (-27.18%)
since 03/15/19
52-Week
89.83 +12.20%
on 06/06/19
315.00 -68.00%
on 07/02/18
-199.37 (-66.42%)
since 06/15/18

Most Recent Stories

More News
Madrigal Pharmaceuticals to Present at Upcoming Investment Conferences

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that Paul Friedman, M.D., Chief Executive Officer of Madrigal, and Becky Taub, M.D., CMO and Executive VP, Research & Development of Madrigal...

MDGL : 100.68 (+3.23%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Certain Officers and Directors of Madrigal Pharmaceuticals, Inc.

Levi & Korsinsky announces it has commenced an investigation of Madrigal Pharmaceuticals, Inc. (NASDAQCM: MDGL) concerning possible breaches of fiduciary duty. To obtain additional information, go to:

MDGL : 100.68 (+3.23%)
Madrigal: 1Q Earnings Snapshot

WEST CONSHOHOCKEN, Pa. (AP) _ Madrigal Pharmaceuticals Inc. (MDGL) on Wednesday reported a loss of $15.1 million in its first quarter.

MDGL : 100.68 (+3.23%)
Madrigal Pharmaceuticals Reports 2019 First Quarter Financial Results and Highlights

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its first quarter 2019 financial results and highlights:

MDGL : 100.68 (+3.23%)
Madrigal Pharmaceuticals to Present Additional Analyses of Data from The Phase 2 NASH Study with MGL-3196 (resmetirom) at The International Liver Congress(TM) 2019

-- MRI-PDFF response (greater-than or equal to30% reduction in hepatic fat) at 12 weeks correlated with reduction in the ballooning and inflammation components of NAS and was predictive of NASH resolution...

MDGL : 100.68 (+3.23%)
Madrigal Pharmaceuticals Initiates Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation

-- Investigator meeting held March 21/22, 2019 --

MDGL : 100.68 (+3.23%)
Intercept (ICPT) Up on Q4 Revenue Beat, NASH Study in Focus

Intercept's (ICPT) Q4 revenues top estimates owing to strong Ocaliva sales, driven by sales force expansion and growth in its foreign geographies.

MRK : 83.30 (+0.63%)
MDGL : 100.68 (+3.23%)
GILD : 67.10 (+1.12%)
ICPT : 84.09 (+5.75%)
Madrigal Pharmaceuticals Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its fourth quarter and full year 2018 financial results and highlights:

MDGL : 100.68 (+3.23%)
Intercept Reports Positive Top-Line Data for NASH, Shares Up

Intercept (ICPT) reports positive top-line results from its pivotal phase III REGENERATE study of OCA in patients with liver fibrosis due to NASH.

MRK : 83.30 (+0.63%)
MDGL : 100.68 (+3.23%)
GILD : 67.10 (+1.12%)
ICPT : 84.09 (+5.75%)
Gilead's (GILD) Late-Stage Study on Liver Disease Drug Fails

Gilead (GILD) suffers a setback as its phase III study on pipeline candidate, selonsertib, in patients with compensated cirrhosis (F4) due to NASH fails to meet goal.

VKTX : 8.14 (+3.56%)
MDGL : 100.68 (+3.23%)
GILD : 67.10 (+1.12%)
ICPT : 84.09 (+5.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade MDGL with:

Business Summary

Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-' agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia...

See More

Key Turning Points

2nd Resistance Point 105.82
1st Resistance Point 101.67
Last Price 100.68
1st Support Level 94.94
2nd Support Level 92.36

See More

52-Week High 315.00
Fibonacci 61.8% 228.99
Fibonacci 50% 202.41
Fibonacci 38.2% 175.84
Last Price 100.68
52-Week Low 89.83

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar